Zenas BioPharma, Inc. (ZBIO)

NASDAQ: ZBIO · Real-Time Price · USD
17.43
+0.38 (2.23%)
At close: Oct 11, 2024, 4:00 PM
17.35
-0.08 (-0.46%)
After-hours: Oct 11, 2024, 5:56 PM EDT
2.23%
Market Cap 728.18M
Revenue (ttm) 50.00M
Net Income (ttm) -54.76M
Shares Out 41.78M
EPS (ttm) -4.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 195,326
Open 17.56
Previous Close 17.05
Day's Range 17.00 - 18.50
52-Week Range 16.17 - 20.50
Beta n/a
Analysts Strong Buy
Price Target 36.75 (+110.84%)
Earnings Date Nov 16, 2024

About ZBIO

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 13, 2024
Employees 114
Stock Exchange NASDAQ
Ticker Symbol ZBIO
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price forecast is $36.75, which is an increase of 110.84% from the latest price.

Price Target
$36.75
(110.84% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

22 days ago - GlobeNewsWire

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand...

Other symbols: BCAXGLXGMBXTDTHXCH
27 days ago - Seeking Alpha

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...

4 weeks ago - GlobeNewsWire

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, in...

Other symbols: BCAXBIOAPMAXPTHL
4 weeks ago - Seeking Alpha

Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials

Zenas BioPharma has filed to raise $100 million in an IPO to advance its Phase 3 and Phase 2 trials for obexelimab, although the final figure may differ. The company is developing antibody-based treat...

6 weeks ago - Seeking Alpha

U.S. IPO Weekly Recap: WeRide Delays Its IPO As Pipeline Gets A Boost

Two small IPOs debuted this past week, while six IPOs submitted initial filings. Six IPOs submitted initial filings this week, including four names which filed to raise $100 million or more. There are...

Other symbols: AZIRITRTDTHWOK
6 weeks ago - Seeking Alpha

Immunology-focused biotech Zenas BioPharma files for an estimated $150 million IPO

Zenas BioPharma, a Phase 3 biotech developing therapies for autoimmune and inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. However, thi...

7 weeks ago - Renaissance Capital

Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO

Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.

7 weeks ago - Reuters

Zenas BioPharma IPO Registration Document (S-1)

Zenas BioPharma has filed to go public with an IPO on the NASDAQ.

7 weeks ago - SEC